Table 1 Characteristics of included studies: all obtain biopsy for identification of CIN2+
First author /publication year | Clinical setting | Index test | Procedure as described in manuscript | Age mean (SD) | Number of women receiving index test | Number of women receiving biopsy (%) | Number of women refusing biopsy | Biopsy indication | Person performing index test | Prior tests | Prevalence of CIN2+ n (%) | Funding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
First-line test | ||||||||||||
 Newman 2019 | Boashan, China | Gynocular™ | Colposcopy traditional Use of green-filter not specified | 44.3 **(6.7) | 488 | 31 (6.3) | NR | Abnormal findings on colposcopy or abnormal cytology | Gynaecologists (1 of 2) | None | 3/488* (0.6%) | Two devices were donated to the study |
Mixed use: first-line test and add-on test | ||||||||||||
 Nessa 2014 Doctors | Dhaka, Bangladesh | Gynocular™ | Colposcopy IARC guidelines | 35.1 (8.1) | 932 | 228 (24.5) | 28 | Women who had a Swede score of greater than 4 | Gynaecologists or Colposcopy trained Physicians (1 of 6) | VIA (n = 528) OR no screening (n = 404) | 39/932* (4.2%) | Two investigators were funded by the device manufacturer |
 Nessa 2014 Nurses | Dhaka, Bangladesh | Gynocular™ | Colposcopy IARC guidelines | 35.1 (8.1) | 932 | 228 (24.5) | 28 | Women who had a Swede score of greater than 4 | Colposcopy trained nurses (1 of 2) | VIA (n = 528) OR no screening (n = 404) | 39/932* (4.2%) | Two investigators were funded by the device manufacturer |
Add-on test only | ||||||||||||
 Banerjee 2018 | West Bengal, India | Gynocular™ | Colposcopy IARC guidelines | 39.2 **(7.4) | 1021 | 1020 (99.9) | 1 | All women who had the index test | Gynaecologist (uncertain how many gynaecologists were performing the index test) | HPV AND /OR VIA (180 had VIA only) | 36/1021 (3.5%) | No funding |
 Kallner 2015 | Stockholm, Sweden | Gynocular™ | Colposcopy IARC guidelines | 33.4 (9.9) | 123 | 113 (92.0) | NR | Women who had a Swede score of greater than 0 | Gynaecologist (1 of 6) | PAP smear AND HPV | 44/123* (35.7%) | One investigator was funded by device manufacturer |
 Mueller 2018 | Lima, Peru | Colposcopy Excluded green filter as not standard practice in Lima | 37.1 *** (20–67) | 129 | 81 (62.7) | NR | Abnormal findings on colposcopy | Physicians (1 of 4) | HPV OR PAP smear | 22/129* (17.1%) | Two National Institutes of Health grants | |